

UC San Diego

UC San Diego Previously Published Works

Title

New Developments on the Treatment of Liver Fibrosis

Permalink

<https://escholarship.org/uc/item/0sb8q1q5>

Journal

Digestive Diseases, 34(5)

ISSN

0257-2753

Authors

Koyama, Yukinori

Xu, Jun

Liu, Xiao

et al.

Publication Date

2016

DOI

10.1159/000445269

Peer reviewed



HHS Public Access

Author manuscript

Dig Dis. Author manuscript; available in PMC 2017 June 22.

Published in final edited form as:

Dig Dis. 2016 ; 34(5): 589–596. doi:10.1159/000445269.

New Developments on the Treatment of Liver Fibrosis

Yukinori Koyama, Jun Xu, Xiao Liu, and David A Brenner

School of Medicine, University of California, San Diego, 9500 Gilman Dr., La Jolla, California 92093

Abstract

Liver fibrosis results from many chronic injuries, and often progresses to cirrhosis, liver failure, portal hypertension, and hepatocellular carcinoma. Liver transplantation is the only treatment available for patients with advanced stages of liver fibrosis. Therefore, new strategies for anti-fibrotic therapy are required. Various kinds of hepatocyte damage result in inflammation which leads to activation of hepatic stellate cells (HSCs), which are the major source of myofibroblasts in the liver. Myofibroblasts proliferate in response to various kinds of cytokines, chemokines, and growth factors and produce extracellular matrix proteins (ECMs), which forms the fibrous scar. Myofibroblasts undergo apoptosis and inactivation when the underlying causative etiologies are cleared. Here we describe our current knowledge of targeting the steps in HSC activation as therapeutic target for liver fibrosis.

Introduction

Liver fibrosis is an ineffective wound-healing process of the liver in response to repeated and chronic injury from many etiologies, such as infectious diseases (e.g., viral hepatitis), metabolic derangements (non-alcoholic steatohepatitis), exposure to toxins (e.g., alcohol liver diseases), or autoimmune diseases (e.g., primary biliary cirrhosis, primary sclerosing cholangitis, and autoimmune hepatitis). The morphology characteristics of liver fibrosis are the deposition of extracellular matrix which is produced by myofibroblasts. Myofibroblasts are absent from the healthy liver, accumulate in the injured liver, and serve as the principle effector cells of fibrogenesis.

Several events are critical for pathogenesis of liver fibrosis and its resolution. Damage to hepatocytes cause inflammatory reactions which lead to activation of hepatic stellate cells (HSCs). HSCs in the normal liver are in a quiescent state and function to store retinoids and serve as the pericytes for the sinusoidal endothelial cells (Fig.1). Continuous liver injury causes perpetuation of activated HSCs, and they become myofibroblasts. Myofibroblasts proliferate in response to various cytokines, chemokines, and growth factors and produce extracellular matrix proteins (ECMs). However, myofibroblasts may undergo apoptosis and inactivation when the underlying causative etiologies are removed (Fig.2). Control and clearance of the underlying causative etiology (e.g., virus suppression or alcohol absence)

Phone: 858-822-5339, Fax: 858-822-0084.

Disclosure Statement

No potential conflict of interest relevant to this article was reported.

can slow down fibrosis progression and lead to fibrosis regression. However, our extensive knowledge on the mechanism leading to liver fibrosis through hepatocyte injury, inflammation, and activation of myofibroblasts to deposit extracellular matrix has not been translated into effective therapies in humans so far (1). In this review we summarize the current knowledge of targeting common pathways that lead to liver fibrosis.

Inhibition of hepatic injury

Liver injury is characterized by hepatocyte damage and death, increased inflammatory cells, and activated HSCs/myofibroblasts. Pharmacological inhibition of liver cell apoptosis may potentially attenuate liver injury, inflammation, and fibrosis by blocking hepatocyte death. Apoptosis is executed by a family of intracellular proteases referred to as caspases(2). For example, a pan-caspase inhibitor IDN-6556 attenuated hepatic injury and fibrosis in mice(3). Furthermore, ocadecic acid (OCA) protects in part from liver fibrosis by protecting hepatocytes from injury (4).

Since reactive oxidative stress (ROS) mediates hepatocyte death, regulating ROS is a promising strategy of liver fibrosis therapy(5). Peroxisome proliferator-activated receptor delta (PPAR δ), a member of the nuclear receptor family, is a key metabolic regulator with pleiotropic actions on various tissues including fat, skeletal muscle, and liver. PPAR δ agonist protects hepatocytes from cell death by reducing ROS generation of hepatocytes, leading to less liver fibrosis (6).

Nonalcoholic fatty liver disease (NAFLD) includes a spectrum of diseases ranging from isolated hepatic steatosis (HIS) to nonalcoholic steatohepatitis (NASH), the progressive form of the disease associated with inflammation and cellular injury, which can lead to cirrhosis. NAFLD has become the most common chronic liver disease in the United States. It is associated with obesity, type 2 diabetes, hyperlipidemia, insulin resistance, and the accumulation of triglycerides in hepatocytes. Although the pathogenesis of the hepatocyte damage in response to lipid accumulation is not fully elucidated, cellular membrane integrity seems to be important for regulating hepatocyte damage. Phosphatidylcholine (PC) is a major component of the cellular membrane, which is generated by a transmethylation reaction from phosphatidylethanolamine via a metabolic pathway that utilizes S-adenosylmethionine (SAdMe) as a methyl donor. The PC/PE ratio may be a key regulator of cell membrane integrity and play a role in the progression of steatosis to NASH. Animal studies show that chronic hepatic SAdMe deficiency causes NASH and HCC. Furthermore, the formation of PC is reduced in various kinds of chronic liver diseases including intrahepatic cholestasis, cholestasis of pregnancy and alcoholic liver disease.

Inhibition of inflammation

Serum amyloid P (SAP) or pentraxin-2, a member of the pentraxin family, is a 27-kDa protein that is produced by the liver, secreted into the blood, and circulates as stable 135-kDa pentamers(7–9). SAP reduces neutrophil adhesion to ECM proteins, inhibits the differentiation of monocytes into fibrocytes, decreases profibrotic macrophages, activates the

complement pathway, and promotes phagocytosis of cell debris. SAP reduces bleomycin-induced lung fibrosis (10). Injection of SAP into humans, mice and rats has no toxic effects.

Inhibition of activation of hepatic stellate cells

After stimulation by cytokines or engulfment of apoptotic bodies, Kupffer cells/macrophage are stimulated to produce TGF- β 1(11, 12), which is a potent cytokine to activate hepatic stellate cells into myofibroblasts with increased expression of α -SMA, TGF- β , PDGF, CTGF, type I collagen, and tissue inhibitor of metalloproteinase 1 (TIMP1) (13). Although TGF- β 1 is one of the most potent stimuli of extracellular matrix synthesis, suppressing its expression remains a major challenge of antifibrotic therapy, since systemic blocking of TGF- β 1 can provoke inflammation and increase the risk of neoplasia. Neutralization of TGF- β in animal models inhibits liver fibrosis and reduces the risk of developing cholangiocarcinoma (14, 15). Fresolimumab (GC1008) is a human anti-TGF- β 1 monoclonal antibody that neutralizes all isoforms of TGF- β . In patients with advanced malignant melanoma and renal cell carcinoma, fresolimumab demonstrated acceptable safety and preliminary evidence of antitumor activity (16–18). Using radio-labeled (89)Zr-conjugated fresolimumab for PET to analyze TGF- β expression, GC1008 accumulated in primary tumors and metastases in a manner similar to IgG (89), and Zr-fresolimumab uptake is seen in sites of tumor ulceration and in scar tissue, where TGF- β is highly active (19). Although there is a phase II clinical trial ongoing of fresolimumab, optimal strategies are still needed to restrict it to the fibrotic milieu. TGF- β transduces its signal to target genes through the ALK5 ser/thr kinase receptor. GW6604 (2-phenyl-4-(3-pyridin-2-yl-1H-pyrazol-4-yl)pyridine), an ALK5 inhibitor, inhibits the transcription and deposition of extracellular matrix and improves the deterioration of liver function in mice (20). Yet, considering of the pleiotropic effects of TGF- β , treatment with an ALK5 inhibitor should be carefully examined to avoid unwanted effects (21).

Integrin α v β 1, which is absent in normal liver but expressed on activated HSCs, promotes liver fibrosis by activating latent TGF- β 1. Selective deletion of integrin α v on HSCs inhibits liver fibrosis (22). A small molecule inhibitor of α v β 1 prevents TGF- β 1 activation and inhibits experimental liver fibrosis (23).

Lysophosphatidic acid (LPA) is a lipid mediator, which is produced mainly by activated platelets via hydrolysis of lysophosphatidylcholine by autotaxin (ATX). LPA is a bioactive lipid implicated in several functions, including proliferation, apoptosis, migration, and cancer cell invasion(24). LPA and LPA1 receptor (LPA1R) are increased in many inflammatory states, including pulmonary fibrosis, liver fibrosis, and systemic sclerosis(25). LPA exerts various physiological effects on the receptors of parenchymal cells and LPA1R antagonists showed anti-fibrotic effect on models of liver fibrosis, lung fibrosis and scleroderma (25–27).

Inhibition of proliferation of HSCs

Inhibitors of receptor tyrosine kinase and Ser/Thr kinase also demonstrate anti-fibrosis effects. The multitargeted receptor tyrosine kinase inhibitor Sorafenib, which has been

approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma (HCC), and Sunitinib can improve experimental hepatic fibrosis, inflammation, and angiogenesis (28, 29). SiRNA of transient receptor potential melastatin 7 (TRPM7), a non-selective cation channel with protein serine/threonine kinase activity, attenuates TGF- β 1-induced expression of myofibroblast markers, increases the ratio of MMPs/TIMPs, and decreases the phosphorylation of Smad2 and Smad3 associated collagen production (30, 31). Hepatic nuclear factor kappa B (NF- κ B)-inducing kinase (NIK), a Ser/Thr kinase, which is increased in injured livers in both, mice and humans, induces hepatocyte injury, activates bone marrow-derived macrophages, and leads to liver fibrosis, and this might serve as a target for liver fibrosis therapy (32).

The renin angiotensin pathway in hepatic stellate cells induces reactive oxygen species and accelerates hepatic fibrosis(33). In response to sustained liver injury, the renin angiotensin system (RAS) locally accelerates inflammation, tissue repair and fibrogenesis by production of angiotensin II (Ang II). RAS is a single cascade where renin converts angiotensinogen into angiotensin I (Ang I), which in turn is converted to angiotensin II (Ang II) by angiotensin converting enzyme (ACE). Ang II mediates biological responses through two G-protein-coupled receptors, the Ang II receptor type 1 (AT1) and Ang II receptor type 2 (AT2). However, the fibrogenic actions of Ang II are mostly mediated by angiotensin receptor AT1. Stimulation of AT₁ receptor by Ang II results in proliferation of HSCs and extracellular matrix deposition. Ang II also plays an important role in ROS formation by activating NADPH oxidase (NOX) in HSCs. In concordance, several experimental models of liver fibrosis in rodents have demonstrated that prolonged administration of angiotensin II directly causes HSC activation. Mice lacking AT₁ receptors are protected from liver fibrosis. This makes RAS an attractive target for anti-fibrotic therapy. Although several small studies showed the usefulness of ACEi/ARB for liver fibrogenesis in patients with hepatitis C (34), the HALT-C cohort study did not show any anti-fibrogenic effects of ACEi/ARB for chronic hepatitis C patients (35).

Activation and proliferation of HSCs requires NADPH oxidase (Nox)/ROS signaling. Chronic liver injury induces ongoing hepatocyte injury and death increases ROS production and decreases antioxidant activity, which is one of the characteristics of chronic liver disease that triggers liver fibrogenesis. NOX produces ROS via transferring electrons from nicotinamide adenine dinucleotide phosphate to molecular oxygen, which is different from other redox enzymes that produce superoxide as a byproduct. The mammalian NOX family is composed of seven isoforms: NOX1, NOX2, NOX3, NOX4, NOX5, DUOX1, and DUOX2, which are distinctively expressed in specific cell types in the liver. Hepatic stellate cells express three Nox isoforms, NOX1, NOX2, and NOX4 (36, 37) (Fig.3). NOX2 is the classic enzyme that phagocytic cells use to produce ROS to kill bacteria, and as such is not a good target for anti-fibrotic therapy. HSCs from p47^{phox}-deficient mice (without a regulatory component of NOX) fail to generate ROS in response to angiotensin II, platelet derived growth factor (PDGF), leptin, or apoptotic bodies, and p47^{phox}-deficient mice demonstrate reduced liver fibrosis after BDL or the hepatotoxin CCl₄ (38, 39). NOX1 and NOX4 are expressed activated HSCs, but only at very low levels in the uninjured liver. GKT137831, a potent dual NOX1/NOX4 inhibitor, attenuates ROS production and inhibits activation of

HSCs (37) and experimental liver fibrosis (40). Multicenter, long-term clinical trials are needed to evaluate the role of antioxidants in NASH.

Promotion of apoptosis of activated HSCs

Daily cannabis use is an independent risk factor for increased liver fibrosis in HCV patients (41). CB1 and CB2 receptors are increased in liver fibrosis. CB1 KO mice are resistant to liver fibrosis, while CB2 KO mice have increased liver fibrosis (42, 43). CB1 agonists activate hepatic stellate cells to myofibroblasts. CB1 receptor agonists, such as Rimonabant, inhibit and reverse experimental liver fibrosis (44, 45). A peripherally acting CB1 antagonist could treat liver fibrosis without inducing depression.

ECM degradation is mediated by matrix metalloproteinases (MMPs), a family of zinc-dependent enzymes grouped into collagenases, gelatinases, stromelysins, and membrane-type MMPs. MMP activity is regulated by tissue inhibitors of metalloproteinases (TIMPs 1–4), which bind in substrate- and tissue-specific manners to MMPs, blocking their proteolytic activity. In concordance, monoclonal Anti-TIMP1 Ab partially reverses established CCl₄ induced fibrosis (46). Furthermore, persistent expression of TIMP-1 in vivo was associated with persistence of activated HSCs, and during resolution of fibrosis, a decrease in TIMP-1 protein levels correlated with decreased numbers of HSCs (47).

Promotion of HSC inactivation

Clinical and experimental hepatic fibrosis is reversible. Regression of liver fibrosis is associated with resorption of fibrous scar and disappearance of collagen producing myofibroblasts. The fate of these myofibroblasts has been recently revealed: Some myofibroblasts undergo apoptosis during regression of fibrosis, while other myofibroblasts revert to a quiescent-like phenotype. Inactivation of myofibroblasts is a newly described phenomenon(48) (Fig.4) which now requires mechanistic investigation. Inactivation of HSCs is associated with re-expression of lipogenic genes PPAR- γ , Insig1, and CREBP. PPAR- γ is reported to be important for maintaining and for re-establishing the quiescent phenotype (qHSCs)(49).

Inhibition of deposition of type I collagen

In liver fibrosis, type I collagen is the most prominent increased components of the extracellular matrix. The cross-linking of type I collagen is also increased, which is modulated by the matrix enzyme lysyloxidase-like-2 (LOXL2). Although blocking collagens have unwanted off-target effects, inhibition of LOXL2 by a monoclonal antibody (AB0023) reduces the production of cytokines, attenuates TGF- β signaling, and inhibits the activate fibroblasts (Barry-Hamilton, 2010. Similar to AB0023, another humanized monoclonal LOXL2 antibody (GS-6624) is in randomized, double blind, phase II clinical trials to treat NASH and PSC(50).

Conclusion

The cellular and molecular mechanism of liver fibrosis has been extensively studied, and new therapies based on these understandings are currently in clinical development. A list of potential therapies for liver fibrosis is provided in Fig.5.

Acknowledgments

Grants: NIH 2 P50 AA011999, 5 P42 ES010337, 5 U01 AA021856

References

1. Hauff P, Gottwald U, Ocker M. Early to Phase II drugs currently under investigation for the treatment of liver fibrosis. *Expert Opin Investig Drugs*. 2015; 24(3):309–327. Epub 2014/12/31. doi: 10.1517/13543784.2015.997874. PubMed PMID: 25547844.
2. Thornberry NA. Caspases: key mediators of apoptosis. *Chem Biol*. 1998; 5(5):R97–R103. Epub 1998/05/14. doi: S1074-5521(98)90615-9 [pii]. PubMed PMID: 9578633. [PubMed: 9578633]
3. Canbay A, Feldstein A, Baskin-Bey E, Bronk SF, Gores GJ. The caspase inhibitor IDN-6556 attenuates hepatic injury and fibrosis in the bile duct ligated mouse. *J Pharmacol Exp Ther*. 2004; 308(3):1191–1196. Epub 2003/11/18. doi: 10.1124/jpet.103.060129 [pii]. PubMed PMID: 14617689. [PubMed: 14617689]
4. Adorini L, Pruzanski M, Shapiro D. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. *Drug Discov Today*. 2012; 17(17–18):988–997. doi: 10.1016/j.drudis.2012.05.012. PubMed PMID: 22652341. [PubMed: 22652341]
5. Koyama Y, Taura K, Hatano E, Tanabe K, Yamamoto G, Nakamura K, Yamanaka K, Kitamura K, Narita M, Nagata H, Yanagida A, Iida T, Iwaisako K, Fujinawa H, Uemoto S. Effects of oral intake of hydrogen water on liver fibrogenesis in mice. *Hepato Res*. 2014; 44(6):663–677. Epub 2013/05/21. doi: 10.1111/hepr.12165. PubMed PMID: 23682614. [PubMed: 23682614]
6. Iwaisako K, Haimerl M, Paik YH, Taura K, Kodama Y, Sirlin C, Yu E, Yu RT, Downes M, Evans RM, Brenner DA, Schnabl B. Protection from liver fibrosis by a peroxisome proliferator-activated receptor delta agonist. *Proc Natl Acad Sci U S A*. 2012; 109(21):E1369–E1376. Epub 2012/04/28. doi: 10.1073/pnas.1202464109 1202464109 [pii]. PubMed PMID: 22538808; PMCID: 3361396. [PubMed: 22538808]
7. Pilling D, Buckley CD, Salmon M, Gomer RH. Inhibition of fibrocyte differentiation by serum amyloid P. *J Immunol*. 2003; 171(10):5537–5546. Epub 2003/11/11. PubMed PMID: 14607961. [PubMed: 14607961]
8. Cox N, Pilling D, Gomer RH. Serum amyloid P: a systemic regulator of the innate immune response. *J Leukoc Biol*. 2014; 96(5):739–743. Epub 2014/05/09. doi: 10.1189/jlb.1MR0114-068R [pii]. PubMed PMID: 24804675. [PubMed: 24804675]
9. Crawford JR, Pilling D, Gomer RH. FcγRIIb mediates serum amyloid P inhibition of fibrocyte differentiation. *J Leukoc Biol*. 2012; 92(4):699–711. Epub 2012/04/12. doi: 10.1189/jlb.0112033 [pii]. PubMed PMID: 22493081; PMCID: 3441318. [PubMed: 22493081]
10. Pilling D, Roife D, Wang M, Ronkainen SD, Crawford JR, Travis EL, Gomer RH. Reduction of bleomycin-induced pulmonary fibrosis by serum amyloid P. *J Immunol*. 2007; 179(6):4035–4044. Epub 2007/09/06. doi: 179/6/4035 [pii]. PubMed PMID: 17785842. [PubMed: 17785842]
11. Fadok VA, McDonald PP, Bratton DL, Henson PM. Regulation of macrophage cytokine production by phagocytosis of apoptotic and post-apoptotic cells. *Biochem Soc Trans*. 1998; 26(4):653–656. Epub 1999/02/27. PubMed PMID: 10047800. [PubMed: 10047800]
12. Szondy Z, Sarang Z, Molnar P, Nemeth T, Piacentini M, Mastroberardino PG, Falasca L, Aeschlimann D, Kovacs J, Kiss I, Szegezdi E, Lakos G, Rajnavolgyi E, Birckbichler PJ, Melino G, Fesus L. Transglutaminase 2^{-/-} mice reveal a phagocytosis-associated crosstalk between macrophages and apoptotic cells. *Proc Natl Acad Sci U S A*. 2003; 100(13):7812–7817. Epub 2003/06/18. doi: 10.1073/pnas.0832466100 0832466100 [pii]. PubMed PMID: 12810961; PMCID: 164670. [PubMed: 12810961]

13. Meindl-Beinker NM, Matsuzaki K, Dooley S. TGF-beta signaling in onset and progression of hepatocellular carcinoma. *Dig Dis*. 2012; 30(5):514–423. Epub 2012/10/31. doi: 10.1159/000341704 000341704 [pii]. PubMed PMID: 23108308. [PubMed: 23108308]
14. Fan X, Zhang Q, Li S, Lv Y, Su H, Jiang H, Hao Z. Attenuation of CCl4-induced hepatic fibrosis in mice by vaccinating against TGF-beta1. *PLoS One*. 2013; 8(12):e82190. Epub 2013/12/19. doi: 10.1371/journal.pone.0082190 PONE-D-13-28963 [pii]. PubMed PMID: 24349218; PMCID: 3859579. [PubMed: 24349218]
15. Ling H, Roux E, Hempel D, Tao J, Smith M, Lonning S, Zuk A, Arbeeny C, Ledbetter S. Transforming growth factor beta neutralization ameliorates pre-existing hepatic fibrosis and reduces cholangiocarcinoma in thioacetamide-treated rats. *PLoS One*. 2013; 8(1):e54499. Epub 2013/01/26. doi: 10.1371/journal.pone.0054499 PONE-D-12-23774 [pii]. PubMed PMID: 23349909; PMCID: 3547926. [PubMed: 23349909]
16. Lacouture ME, Morris JC, Lawrence DP, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Berzofsky JA, Hsu FJ, Guitart J. Cutaneous keratoacanthomas/squamous cell carcinomas associated with neutralization of transforming growth factor beta by the monoclonal antibody fresolimumab (GC1008). *Cancer Immunol Immunother*. 2015; 64(4):437–446. Epub 2015/01/13. doi: 10.1007/s00262-015-1653-0. PubMed PMID: 25579378. [PubMed: 25579378]
17. Morris JC, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Reiss M, Hsu FJ, Berzofsky JA, Lawrence DP. Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. *PLoS One*. 2014; 9(3):e90353. Epub 2014/03/13. doi: 10.1371/journal.pone.0090353 PONE-D-13-39360 [pii]. PubMed PMID: 24618589; PMCID: 3949712. [PubMed: 24618589]
18. Trachtman H, Fervenza FC, Gipson DS, Heering P, Jayne DR, Peters H, Rota S, Remuzzi G, Rump LC, Sellin LK, Heaton JP, Streisand JB, Hard ML, Ledbetter SR, Vincenti F. A phase I, single-dose study of fresolimumab, an anti-TGF-beta antibody, in treatment-resistant primary focal segmental glomerulosclerosis. *Kidney Int*. 2011; 79(11):1236–1243. Epub 2011/03/04. doi: 10.1038/ki.2011.33 ki201133 [pii]. PubMed PMID: 21368745; PMCID: 3257033. [PubMed: 21368745]
19. Oude Munnink TH, Arjaans ME, Timmer-Bosscha H, Schroder CP, Hesselink JW, Vedelaar SR, Walenkamp AM, Reiss M, Gregory RC, Lub-de Hooge MN, de Vries EG. PET with the 89Zr-labeled transforming growth factor-beta antibody fresolimumab in tumor models. *J Nucl Med*. 2011; 52(12):2001–2208. Epub 2011/11/11. doi: 10.2967/jnumed.111.092809 [pii]. PubMed PMID: 22072706. [PubMed: 22072706]
20. de Gouville AC, Boullay V, Krysa G, Pilot J, Brusq JM, Loriolle F, Gauthier JM, Papworth SA, Laroze A, Gellibert F, Huet S. Inhibition of TGF-beta signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis. *Br J Pharmacol*. 2005; 145(2):166–177. Epub 2005/02/22. doi: 0706172 [pii] 10.1038/sj.bjp.0706172. PubMed PMID: 15723089; PMCID: 1576127. [PubMed: 15723089]
21. de Gouville AC, Huet S. Inhibition of ALK5 as a new approach to treat liver fibrotic diseases. *Drug News Perspect*. 2006; 19(2):85–90. Epub 2006/04/22. doi: 977444 [pii] 10.1358/dnp.2006.19.2.977444. PubMed PMID: 16628263. [PubMed: 16628263]
22. Henderson NC, Arnold TD, Katamura Y, Giacomini MM, Rodriguez JD, McCarty JH, Pellicoro A, Raschperger E, Betsholtz C, Ruminiski PG, Griggs DW, Prinsen MJ, Maher JJ, Iredale JP, Lacy-Hulbert A, Adams RH, Sheppard D. Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs. *Nat Med*. 2013; 19(12):1617–1624. doi: 10.1038/nm.3282. PubMed PMID: 24216753; PMCID: PMC3855865. [PubMed: 24216753]
23. Reed NI, Jo H, Chen C, Tsujino K, Arnold TD, DeGrado WF, Sheppard D. The alphavbeta1 integrin plays a critical in vivo role in tissue fibrosis. *Sci Transl Med*. 2015; 7(288):288ra79. doi: 10.1126/scitranslmed.aaa5094. PubMed PMID: 25995225; PMCID: PMC4461057.
24. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. *Nat Rev Cancer*. 2003; 3(8):582–591. Epub 2003/08/02. doi: 10.1038/nrc1143 [pii]. PubMed PMID: 12894246. [PubMed: 12894246]
25. Mazzocca A, Dituri F, Lupo L, Quaranta M, Antonaci S, Giannelli G. Tumor-secreted lysophosphatidic acid accelerates hepatocellular carcinoma progression by promoting differentiation

- of peritumoral fibroblasts in myofibroblasts. *Hepatology*. 2011; 54(3):920–930. Epub 2011/06/16. doi: 10.1002/hep.24485. PubMed PMID: 21674557. [PubMed: 21674557]
26. Ohashi T, Yamamoto T. Anti-fibrotic effect of lysophosphatidic acid receptors LPA and LPA antagonist on experimental murine scleroderma induced by bleomycin. *Exp Dermatol*. 2015 Epub 2015/05/12. doi: 10.1111/exd.12752. PubMed PMID: 25959255.
 27. Swaney JS, Chapman C, Correa LD, Stebbins KJ, Bunday RA, Prodanovich PC, Fagan P, Baccei CS, Santini AM, Hutchinson JH, Seiders TJ, Parr TA, Prasit P, Evans JF, Lorrain DS. A novel, orally active LPA(1) receptor antagonist inhibits lung fibrosis in the mouse bleomycin model. *Br J Pharmacol*. 2010; 160(7):1699–1713. Epub 2010/07/24. doi: 10.1111/j.1476-5381.2010.00828.x BPH828 [pii]. PubMed PMID: 20649573; PMCID: 2936842. [PubMed: 20649573]
 28. Mejias M, Garcia-Pras E, Tiani C, Miquel R, Bosch J, Fernandez M. Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. *Hepatology*. 2009; 49(4):1245–156. Epub 2009/01/13. doi: 10.1002/hep.22758. PubMed PMID: 19137587. [PubMed: 19137587]
 29. Tugues S, Fernandez-Varo G, Munoz-Luque J, Ros J, Arroyo V, Rodes J, Friedman SL, Carmeliet P, Jimenez W, Morales-Ruiz M. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. *Hepatology*. 2007; 46(6):1919–1926. Epub 2007/10/16. doi: 10.1002/hep.21921. PubMed PMID: 17935226. [PubMed: 17935226]
 30. Fang L, Zhan S, Huang C, Cheng X, Lv X, Si H, Li J. TRPM7 channel regulates PDGF-BB-induced proliferation of hepatic stellate cells via PI3K and ERK pathways. *Toxicol Appl Pharmacol*. 2013; 272(3):713–725. Epub 2013/08/21. doi: 10.1016/j.taap.2013.08.009 S0041-008X(13)00359-1 [pii]. PubMed PMID: 23958495. [PubMed: 23958495]
 31. Fang L, Huang C, Meng X, Wu B, Ma T, Liu X, Zhu Q, Zhan S, Li J. TGF-beta1-elevated TRPM7 channel regulates collagen expression in hepatic stellate cells via TGF-beta1/Smad pathway. *Toxicol Appl Pharmacol*. 2014; 280(2):335–344. Epub 2014/08/26. doi: 10.1016/j.taap.2014.08.006 S0041-008X(14)00298-1 [pii]. PubMed PMID: 25150141. [PubMed: 25150141]
 32. Shen H, Sheng L, Chen Z, Jiang L, Su H, Yin L, Omary MB, Rui L. Mouse hepatocyte overexpression of NF-kappaB-inducing kinase (NIK) triggers fatal macrophage-dependent liver injury and fibrosis. *Hepatology*. 2014; 60(6):2065–2076. Epub 2014/08/05. doi: 10.1002/hep.27348. PubMed PMID: 25088600; PMCID: 4245385. [PubMed: 25088600]
 33. Kisseleva T, Brenner DA. Anti-fibrogenic strategies and the regression of fibrosis. *Best Pract Res Clin Gastroenterol*. 2011; 25(2):305–317. Epub 2011/04/19. doi: 10.1016/j.bpg.2011.02.011 S1521-6918(11)00037-0 [pii]. PubMed PMID: 21497747; PMCID: 3086317. [PubMed: 21497747]
 34. Corey KE, Shah N, Misdraji J, Abu Dayyeh BK, Zheng H, Bhan AK, Chung RT. The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. *Liver Int*. 2009; 29(5):748–753. Epub 2009/02/18. doi: 10.1111/j.1478-3231.2009.01973.x LIV1973 [pii]. PubMed PMID: 19220742; PMCID: 3151254. [PubMed: 19220742]
 35. Abu Dayyeh BK, Yang M, Dienstag JL, Chung RT. The effects of angiotensin blocking agents on the progression of liver fibrosis in the HALT-C Trial cohort. *Dig Dis Sci*. 2011; 56(2):564–568. Epub 2010/12/08. doi: 10.1007/s10620-010-1507-8. PubMed PMID: 21136163; PMCID: 3142358. [PubMed: 21136163]
 36. Paik YH, Iwaisako K, Seki E, Inokuchi S, Schnabl B, Osterreicher CH, Kisseleva T, Brenner DA. The nicotinamide adenine dinucleotide phosphate oxidase (NOX) homologues NOX1 and NOX2/gp91(phox) mediate hepatic fibrosis in mice. *Hepatology*. 2011; 53(5):1730–1741. doi: 10.1002/hep.24281. PubMed PMID: 21384410; PMCID: 3082608. [PubMed: 21384410]
 37. Paik YH, Kim J, Aoyama T, De Minicis S, Bataller R, Brenner DA. Role of NADPH oxidases in liver fibrosis. *Antioxid Redox Signal*. 2014; 20(17):2854–2872. Epub 2013/09/18. doi: 10.1089/ars.2013.5619. PubMed PMID: 24040957; PMCID: 4026397. [PubMed: 24040957]
 38. De Minicis S, Brenner DA. NOX in liver fibrosis. *Arch Biochem Biophys*. 2007; 462(2):266–272. Epub 2007/05/29. doi: S0003-9861(07)00205-6 [pii] 10.1016/j.abb.2007.04.016. PubMed PMID: 17531188; PMCID: 2727549. [PubMed: 17531188]
 39. De Minicis S, Seki E, Paik YH, Osterreicher CH, Kodama Y, Kluwe J, Torozzi L, Miyai K, Benedetti A, Schwabe RF, Brenner DA. Role and cellular source of nicotinamide adenine dinucleotide phosphate oxidase in hepatic fibrosis. *Hepatology*. 2010; 52(4):1420–1430. Epub

- 2010/08/07. doi: 10.1002/hep.23804. PubMed PMID: 20690191; PMCID: 2947612. [PubMed: 20690191]
40. Lan T, Kisseleva T, Brenner DA. Deficiency of NOX1 or NOX4 Prevents Liver Inflammation and Fibrosis in Mice through Inhibition of Hepatic Stellate Cell Activation. *PLoS one*. 2015; 10(7):e0129743. doi: 10.1371/journal.pone.0129743. PubMed PMID: 26222337; PMCID: PMC4519306. [PubMed: 26222337]
41. Patsenker E, Sachse P, Chicca A, Gachet MS, Schneider V, Mattsson J, Lanz C, Worni M, de Gottardi A, Semmo M, Hampe J, Schafmayer C, Brenneisen R, Gertsch J, Stickel F, Semmo N. Elevated levels of endocannabinoids in chronic hepatitis C may modulate cellular immune response and hepatic stellate cell activation. *Int J Mol Sci*. 2015; 16(4):7057–7076. Epub 2015/04/01. doi: 10.3390/ijms16047057 [pii]. PubMed PMID: 25826533; PMCID: 4425004. [PubMed: 25826533]
42. Julien B, Grenard P, Teixeira-Clerc F, Van Nhieu JT, Li L, Karsak M, Zimmer A, Mallat A, Lotersztajn S. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. *Gastroenterology*. 2005; 128(3):742–755. Epub 2005/03/15. doi: S0016508504023534 [pii]. PubMed PMID: 15765409. [PubMed: 15765409]
43. Pacher P, Gao B. Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases. *Am J Physiol Gastrointest Liver Physiol*. 2008; 294(4):G850–G854. Epub 2008/02/02. doi: 10.1152/ajpgi.00523.2007 00523.2007 [pii]. PubMed PMID: 18239059; PMCID: 2376822. [PubMed: 18239059]
44. Dai E, Zhang J, Zhang D, Yang L, Wang Y, Jiang X, Ye L, Li X, Liu H, Ma J, Jiang H. Rimobant inhibits proliferation, collagen secretion and induces apoptosis in hepatic stellate cells. *Hepatogastroenterology*. 2014; 61(135):2052–2061. Epub 2015/02/26. PubMed PMID: 25713910. [PubMed: 25713910]
45. Baldassarre M, Giannone FA, Napoli L, Tovoli A, Ricci CS, Tufoni M, Caraceni P. The endocannabinoid system in advanced liver cirrhosis: pathophysiological implication and future perspectives. *Liver Int*. 2013; 33(9):1298–1308. Epub 2013/07/31. doi: 10.1111/liv.12263. PubMed PMID: 23890208. [PubMed: 23890208]
46. Parsons CJ, Bradford BU, Pan CQ, Cheung E, Schauer M, Knorr A, Krebs B, Kraft S, Zahn S, Brocks B, Feirt N, Mei B, Cho MS, Ramamoorthi R, Roldan G, Ng P, Lum P, Hirth-Dietrich C, Tomkinson A, Brenner DA. Antifibrotic effects of a tissue inhibitor of metalloproteinase-1 antibody on established liver fibrosis in rats. *Hepatology*. 2004; 40(5):1106–1115. Epub 2004/09/25. doi: 10.1002/hep.20425. PubMed PMID: 15389776. [PubMed: 15389776]
47. Murphy FR, Issa R, Zhou X, Ratnarajah S, Nagase H, Arthur MJ, Benyon C, Iredale JP. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects on matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. *J Biol Chem*. 2002; 277(13):11069–11076. Epub 2002/01/18. doi: 10.1074/jbc.M111490200 M111490200 [pii]. PubMed PMID: 11796725. [PubMed: 11796725]
48. Kisseleva T, Cong M, Paik Y, Scholten D, Jiang C, Benner C, Iwaisako K, Moore-Morris T, Scott B, Tsukamoto H, Evans SM, Dillmann W, Glass CK, Brenner DA. Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis. *Proc Natl Acad Sci U S A*. 2012; 109(24):9448–9453. Epub 2012/05/09. doi: 10.1073/pnas.1201840109 1201840109 [pii]. PubMed PMID: 22566629; PMCID: 3386114. [PubMed: 22566629]
49. Liu X, Xu J, Brenner DA, Kisseleva T. Reversibility of Liver Fibrosis and Inactivation of Fibrogenic Myofibroblasts. *Curr Pathobiol Rep*. 2013; 1(3):209–214. Epub 2013/09/04. doi: 10.1007/s40139-013-0018-7. PubMed PMID: 24000319; PMCID: 3757252. [PubMed: 24000319]
50. Schuppan D, Kim YO. Evolving therapies for liver fibrosis. *J Clin Invest*. 2013; 123(5):1887–1901. Epub 2013/05/03. doi: 10.1172/JCI66028 66028 [pii]. PubMed PMID: 23635787; PMCID: 3635731. [PubMed: 23635787]





Fig. 1.
The characteristics of activated hepatic stellate cells (HSCs).

**Fig. 2.**

Phenotypic pathway of hepatic stellate cells (HSCs).

Hepatocyte damage causes an inflammatory reaction which leads to activation of hepatic stellate cells (HSCs). Continuous liver injury causes perpetuation of activated HSCs in the liver, and they become myofibroblasts. Myofibroblasts proliferate in response to various kinds of cytokines and produce extracellular matrix proteins (ECMs). Myofibroblasts undergo apoptosis or inactivation when the underlying causative etiologies are cleared.

NOX1

- Non-phagocytic form of NOX
- Expressed in VSMCs and fibroblasts
- Induced by Ang II, Leptin, PDGF

NOX2

- Classic phagocytic form of NOX
- Expressed in macrophages
- Inducible

NOX4

- Regulated at level of transcription
- Increased in inflammation and fibrosis
- Induced by TGF β






Fig. 3.
NADPH oxidases (NOXs) present in hepatic stellate cells.




Fig. 4.
Activation and inactivation of hepatic stellate cells (HSCs).

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Angiotensin Receptor Blockers

Vitamin E

PPAR γ agonists

IL4/IL13 dual antibody

LPA1 receptor antagonists

Av β 6 antibody

Tyrosine kinase inhibitors

ACE I, ARBs

Perferidone

OCA

TIMP-1 antibody

PPAR δ agonists

TGF β inhibitors

Human Pentraxin-2

LOXL2 antibody

Prolyl hydroxylase inhibitors

Hedgehog inhibitors

CB1 inhibitors

Caspase inhibitors

Galactin-3 inhibitor

Fig. 5.
Proposed therapies for liver fibrosis.